Microscopic transduodenal excision of an ampullary adenoma: A case report and review of the literature

paythelady.612 shared this article with you from Inoreader Microscopic transduodenal excision of an ampullary adenoma: A case report and review of the literature Μέσω pubmed: "world j clin cases"... World J Clin Cases. 2021 Jun 26;9(18):4844-4851. doi: 10.12998/wjcc.v9.i18.4844. ABSTRACT BACKGROUND: Transduodenal local excision is an alternative treatment approach for benign ampullary tumors. However, this procedure has technical difficulties, especially during reconstruction of the pancreaticobiliary ducts. An operating microscope has been widely used by surgeons for delicate surgery due to its major advantages of magnification, illumination, and stereoscopic view. The application of an operating microscope in transduodenal excision of ampullary tumors has not been reported. CASE SUMMARY: A 55-year-old woman was admitted for investigation of recurrent upper abdominal pain. Physical examination and laboratory tests found no abnormalities. Imaging identified a large mass in the descending part of the duodenum. Esophagogastroduodenoscopy revealed a 3.5-cm-sized villous growth over the major duodenal papilla. Pathology of the e ndoscopic biopsy indicated a villous adenoma with low-grade dysplasia. Microscopic transduodenal excision of the ampullary tumor was performed. The final pathological diagnosis was villous-tubular adenoma with low-grade dysplasia. The patient was discharged on postoperative day 12 after an uneventful recovery. Endoscopic retrograde cholangiopancreatography was performed 3 mo postoperatively and showed no bile duct or pancreatic duct strictures and no tumor recurrence. The patient is continuing follow-up at our clinic and remains well. CONCLUSION: Operating microscope-assisted transduodenal local excision is a feasible and effective option for benign ampullary tumors. PMID:34222457 | PMC:PMC8223850 | DOI:10.12998/wjcc.v9.i18.4844 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.